By: Karishma Jain, Himani Chandna
While the earlier biopharma mission focused on innovation and pipeline building, the new scheme will place greater emphasis on commercial manufacturing and product market readiness
Himani Chandna is an Associate Editor at CNN News18. She specializes in healthcare and pharmaceuticals, with a focus on making complex medical topics accessible and engaging for all audiences. Featured in Firstpost and CNN-News18, Himani is passionate about reporting on medical miracles, treatment breakthroughs, and the evolving landscape of health, drawing from her extensive insights into India's COVID-19 battle and various health-related themes.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)


Not enough data
Himani Chandna's coverage primarily focuses on healthcare and pharmaceutical topics in India. She often reports on government announcements and frequently cites data.
To effectively reach out to Himani, consider providing insights related to Indian healthcare policies, pharmaceutical regulations, or drug quality control issues. Additionally, offering access to relevant data or statistics may enhance the appeal of your pitch as she regularly incorporates cited data into her articles.
Given her focus on national (India) matters within the healthcare sector, experts with firsthand experience in Indian pharmaceutical regulations and trade agreements would be well-suited for potential contributions to her articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .